FDA Biosimilar Approval Foreshadows IP Litigation Issues
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time.[1]...To view the full article, register now.
Already a subscriber? Click here to view full article